AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12903700
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline flushes (1 mL)
Trial: 2015168
Drug: Pinacidil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil (25 mg, sustained release formulation)
Trial: 6794086
Drug: Lysine-8-vasopressin (LVP)
RxNorm normalized name: Vasopressin, 8-L-lysine
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lysine-8-vasopressin (LVP) at a dosage starting from 22.5 IU/day to 67.5 IU/day over 3 weeks
Trial: 30639574
Drug: Preventive intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive intramuscular use of 5 mg phenylephrine
Trial: 30639574
Drug: Preventive intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive intravenous use of 100 μg phenylephrine
Trial: 28490464
Drug: β-adrenergic antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: β-adrenergic antagonist (propranolol) and COX-2 inhibitor (etodolac) for 11 days, starting 5 days before surgery
Trial: 19951210
Drug: Balance exercises
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance exercises (11 exercises, twice per week)
Trial: 9451748
Drug: rIL-2 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIL-2 with chemotherapy (5-fluorouracil and leucovorin)
Trial: 15374271
Drug: Ipriflavone (IP)
RxNorm normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipriflavone (IP) 3 x 200 mg/day
Trial: 2828820
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 mg/d for 5 days)
Trial: 25646357
Drug: 2-weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF)
Trial: 18186564
Drug: Pegylated-interferon alpha-2a
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated-interferon alpha-2a (135 microg weekly for 48 weeks)
Trial: 17213004
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (S‐amlodipine 5 mg p.o.)
Trial: 17213004
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (racemate 10 mg p.o.)
Trial: 8643897
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy (BEAM) with autologous stem cell rescue
Trial: 1448312
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms of recombinant hepatitis B vaccine (Engerix B) at zero, 1 and 6 months
Trial: 1448312
Drug: 2 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 micrograms of recombinant hepatitis B vaccine (Engerix B) at zero, 1 and 2 months
Trial: 1448312
Drug: 2 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 micrograms of recombinant hepatitis B vaccine (Engerix B) at zero, 1 and 2 months (specific subgroup)
Trial: 3882143
Drug: Domperidone 10
RxNorm normalized name: domperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 10 mg, three times daily
Trial: 3882143
Drug: Domperidone 20
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 20 mg (single dose)
Trial: 19136303
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate 15 mg weekly for 40 weeks (7.5 mg weekly for 4 weeks, then 10 mg weekly for 4 weeks, then 15 mg weekly for 32 weeks)
Trial: 9741509
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg/day + colestipol 20 g/day
Trial: 8000839
Drug: iomeprol-300 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol-300 (300 mg I ml-1)
Trial: 8000839
Drug: iopromide-300 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopromide-300 (300 mg I ml-1)
Trial: 20418538
Drug: Methadone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (0.2 mg/kg) before surgical incision
Trial: 20418538
Drug: Sufentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil infusion (0.25 μg/kg/h after a load of 0.75 μg/kg)
Trial: 16480794
Drug: TdPa formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TdPa formulations with inactivated poliomyelitis vaccine (IPV)
Trial: 16480794
Drug: TdPa formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TdPa formulations without inactivated poliomyelitis vaccine (IPV)
Trial: 16480794
Drug: Mouse booster
RxNorm normalized name: house mouse skin extract
DrugBank: Mus musculus skin (DB10412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouse booster model with whole cell pertussis vaccine priming
Trial: 12562658
Drug: Granisetron 2
RxNorm normalized name: granisetron 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 2 mg p.o. on day 1, followed by dexamethasone 4 mg p.o. od for 5 days
Trial: 12562658
Drug: Metoclopramide 20
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 20 mg p.o. tds combined with dexamethasone 4 mg p.o. od for 5 days
Trial: 9302466
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy at 2 atmospheres absolute pressure
Trial: 9302466
Drug: Air treatment
RxNorm normalized name: GLYCERIN 3.88 mg in 1 mL TOPICAL SHAMPOO [HAIR TREATMENT PREMIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air treatment at 1.1 atmosphere absolute pressure
Trial: 3098270
Drug: Ro 15-1788
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15-1788 (0.5 mg intravenous bolus)
Trial: 26481332
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (re-esterified triacylglycerol fish oil capsule)
Trial: 25304298
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy and radical hypofractionated radiotherapy (cisplatinum and vinorelbine with 55Gy in 20 fractions over four weeks)
Trial: 25304298
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy and radical hypofractionated radiotherapy (cisplatinum and vinorelbine with 55Gy in 20 fractions over four weeks)
Trial: 25304298
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy and radical hypofractionated radiotherapy
Trial: 12912859
Drug: IFN‐beta‐1a (22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐beta‐1a (22 micro g three times a week subcutaneously, increased to 44 micro g and then to 88 micro g if no response, maximum duration of treatment 8 weeks)
Trial: 7000128
Drug: Fenoterol 2
RxNorm normalized name: fenoterol 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol 2 mg administered by intermittent positive pressure breathing (IPPB) in 40% oxygen
Trial: 7000128
Drug: Terbutaline 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 10 mg administered by intermittent positive pressure breathing (IPPB) in 40% oxygen
Trial: 24065443
Drug: Prasugrel 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 60 mg LD alone
Trial: 24065443
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg plus prasugrel 60 mg
Trial: 24065443
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg plus prasugrel 30 mg
Trial: 21220618
Drug: Weekly doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly doxorubicin and daily oral cyclophosphamide with granulocyte colony-stimulating factor support for 15 weeks (continuous arm)
Trial: 21220618
Drug: Standard doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doxorubicin and cyclophosphamide administered for five cycles (standard arm)
Trial: 21220618
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel for 12 weeks before surgery (both arms)
Trial: 31732233
Drug: Monthly blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly blood sampling
Trial: 20066450
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) 40 mg every other week
Trial: 27147222
Drug: MRgFUS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRgFUS treatment
Trial: 24351233
Drug: Pregabalin 450-600
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 450-600 mg/d
Trial: 24351233
Drug: Pregabalin 150-300
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150-300 mg/d
Trial: 24351233
Drug: Lorazepam 3-4
RxNorm normalized name: lorazepam 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 3-4 mg/d
Trial: 24351233
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Pregabalin and Lorazepam)
Trial: 22664339
Drug: Topical eprinomectin
RxNorm normalized name: eprinomectin Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical eprinomectin (≥ 0.05 mg/kg) every 28 days for eight treatments during lactation
Trial: 16135464
Drug: Schedule A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule A (pemetrexed 500 mg/m2 followed by gemcitabine 1,250 mg/m2 on day 1 and gemcitabine on day 8)
Trial: 10099065
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg nebivolol once daily
Trial: 10099065
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nifedipine retard twice daily
Trial: 28164346
Drug: Palmithoylethanolamide/polydatin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmithoylethanolamide/polydatin 200 mg/20 mg
Trial: 26994230
Drug: extrafascial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: extrafascial injection
Trial: 26994230
Drug: conventional intrafascial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional intrafascial injection
Trial: 24608069
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg film-coated tablet (fasted)
Trial: 24608069
Drug: four 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four 100 mg EC tablets (fasted)
Trial: 24608069
Drug: one 400
RxNorm normalized name: dipyrone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one 400 mg GFS dose (fasted)
Trial: 24608069
Drug: four 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four 100 mg EC tablets (after a high-fat meal)
Trial: 22568162
Drug: VCT/VCUG combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCT/VCUG combination group
Trial: 17177199
Drug: Quetiapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (mean dose 182 mg/day)
Trial: 14667422
Drug: Node-link mapping
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Node-link mapping group treatment (n=4)
Trial: 14667422
Drug: Non-mapping group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-mapping group treatment (n=4)
Trial: 14667422
Drug: Node-link mapping
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Node-link mapping group treatment (n=9 in Experiment 2)
Trial: 11724078
Drug: PAS granules
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAS granules (6 g) with high-fat food
Trial: 11724078
Drug: PAS granules
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAS granules (6 g) with orange juice
Trial: 11724078
Drug: PAS granules
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAS granules (6 g) with food
Trial: 11724078
Drug: PAS granules
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAS granules (6 g) with antacids
Trial: 9190323
Drug: Tramadol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (up to 600mg daily, mean daily dose 250 to 290mg)
Trial: 9190323
Drug: Clomipramine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (up to 100mg daily, mean daily dose 59.1 to 63.6mg) with or without levomepromazine (100mg)
Trial: 7955956
Drug: Aminoglutethimide (AG;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (AG; 500 mg daily plus hydrocortisone 40 mg daily)
Trial: 7955956
Drug: Medroxyprogesterone (MPA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone (MPA; 1,000 mg daily per os)
Trial: 29497150
Drug: IND (indapamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IND (indapamide 1.25-2.5 mg daily)
Trial: 29497150
Drug: IND/KCl (indapamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IND/KCl (indapamide 1.25-2.5 mg daily plus potassium chloride 40 mmol daily)
Trial: 23254962
Drug: Inductive chemotherapy
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inductive chemotherapy plus radiation therapy (IC + RT) with 2-3 cycles of cisplatin (80 mg/m²) and fluorouracil (500 mg/m²), followed by radiotherapy.
Trial: 23254962
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CCRT) with weekly cisplatin (40 mg/m²) for 6-7 cycles during radiotherapy.
Trial: 23254962
Drug: Inductive chemotherapy
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inductive chemotherapy plus concurrent chemoradiotherapy (IC + CCRT) with similar chemotherapy regimen as IC + RT followed by CCRT regimen.
Trial: 23254962
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy alone (RT).
Trial: 19854590
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg IV single dose)
Trial: 10579275
Drug: Standard enteral
RxNorm normalized name: Standard enteral formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard enteral nutrition (gradually increased from 15 mL/hr up to estimated energy and nitrogen requirements)
Trial: 1744924
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of leucovorin
Trial: 1744924
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of leucovorin
Trial: 6126069
Drug: Communication-oriented group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Communication-oriented group therapy
Trial: 21705294
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg daily for 12 weeks
Trial: 20074897
Drug: Water 0.1
RxNorm normalized name: nitroglycerin in 5 % dextrose in water 0.1 mg/mL INTRAVEN INFUSION BOTTLE (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water 0.1 ml/kg (G2)
Trial: 17409263
Drug: Glucose supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose supplements (G) - 6.13 +/‐ 0.09% glucose
Trial: 14986145
Drug: Contrast enhancement
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast enhancement administered in 11 cases
Trial: 11566640
Drug: Psyllium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium supplement (15 g psyllium/d)
Trial: 7868693
Drug: Medical abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical abortion (mifepristone 600 mg followed by gemeprost 1 mg vaginal pessary)
Trial: 29956790
Drug: Isomaltulose (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomaltulose (20 g)
Trial: 26754305
Drug: Levothyroxine soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine soft capsules (600 μg)
Trial: 26754305
Drug: Levothyroxine tablets
RxNorm normalized name: levothyroxine Oral Tablet
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine tablets (200 μg)
Trial: 26754305
Drug: Low, medium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low, medium, and high strengths of levothyroxine soft capsules
Trial: 20631675
Drug: Erythropoiesis-stimulating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis-stimulating agents (ESA) treatment
Trial: 18614402
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg slow release indapamide, with the option of 2‐4 mg perindopril
Trial: 8966389
Drug: ACTH stimulation
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH stimulation test (0.25 mg iv bolus)
Trial: 8966389
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral midnight DEX inhibition test
Trial: 8966389
Drug: 100-g 2-h
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-g 2-h oral glucose tolerance test (OGTT)
Trial: 8966389
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of basal luteinizing hormone (LH) and follicle-stimulating hormone (FSH) ratio
Trial: 6125820
Drug: Daily bag-changing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily bag-changing regimen
Trial: 6125820
Drug: Weekly bag-changing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly bag-changing regimen
Trial: 31487279
Drug: Antibacterial treatment
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial treatment
Trial: 31469393
Drug: Sequential choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential choice (colonoscopy and then FIT)
Trial: 26273677
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and rosiglitazone 4 mg/day (n = 30)
Trial: 26273677
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone (n = 31)
Trial: 19502256
Drug: Rapamycin-eluting stents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin-eluting stents with adjunct oral valsartan
Trial: 15852444
Drug: Memantine 10
RxNorm normalized name: Memantine 10mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 10 mg b.i.d.
Trial: 11961446
Drug: Short-term intravenous
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term intravenous antibiotics (7 days for joint infection, 10 days for bone infection)
Trial: 11961446
Drug: Long-term intravenous
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term intravenous antibiotics (14 days for joint infection, 21 days for bone infection)
Trial: 7661494
Drug: Cefixime (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (400 mg every 24 hours for 5 days)
Trial: 7661494
Drug: Pivamdinocillin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivamdinocillin (400 mg every 6 hours for 5 days)
Trial: 30544335
Drug: IL13‐Pseudomonas exotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL13‐Pseudomonas exotoxin (IL13‐PE38QQR) administered via intratumoral convection enhanced delivery (CED) at 0.125 µg/mL
Trial: 30544335
Drug: IL13‐Pseudomonas exotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL13‐Pseudomonas exotoxin (IL13‐PE38QQR) administered via intratumoral convection enhanced delivery (CED) at 0.25 µg/mL
Trial: 30544335
Drug: IL13‐Pseudomonas exotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL13‐Pseudomonas exotoxin (IL13‐PE38QQR) administered via CED
Trial: 25022834
Drug: Exceeding Recommended
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exceeding Recommended Daily Upper Level for sodium intake at 18 months
Trial: 27718262
Drug: Tulobuterol patch
RxNorm normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol patch (TP)
Trial: 20440023
Drug: Simulated Developmental
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated Developmental Horse‐Riding Program (SDHRP) in addition to regular occupational therapy
Trial: 20440023
Drug: Regular occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular occupational therapy only
Trial: 18702964
Drug: Aggressive LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive LDL-C lowering with lovastatin 40 to 80 mg/day (target LDL-C of 60 to 85 mg/dl)